Larissa S Carnevalli

17PUBLICATIONS
114CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCarbon capture engineering (excl. sequestration)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jun 20, 2025
A linear ontogeny accounts for the development of naive, memory, and tumor-infiltrating regulatory T cells in mice.

Sanmoy Pathak, Thea Hogan, Sanket Rane

|Feb 24, 2024
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.

Elizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar

|Sep 19, 2023
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

Lorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson

|Sep 19, 2023
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.

Mandy Lawson, Natalie Cureton, Susana Ros

|Aug 18, 2023
Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

Lorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson

|Aug 05, 2023
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

Lorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson

Pageof 3

Frequent Collaborators

8 joint publications

Simon T Barry

5 joint publications

Adina M Hughes

4 joint publications

Stuart C Williamson

4 joint publications

Susana Ros